VCYT Earnings

VCYT reported its earnings on 2026-02-25, showcasing a revenue of against an estimate of 138.68M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.28 by 0%. The stock experienced a 8.48% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following VCYT's earnings announcement on 2026-02-25, the stock price moved by 8.48% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, VCYT's stock price tends to shift by an average of 1.78% in the 10 days leading up to earnings and 4.9% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate VCYT's annual revenue to reach 130.43M, while the EPS is projected at 0.34. These estimates reflect recent revisions, with revenue estimates revised downward by -0.01% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between VCYT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised downward by -0.01%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, VCYT's stock price typically moves by 1.78% in the 10 days before its earnings and 4.9% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.34 and revenue of 130.43M.

The earnings call summary reflects strong financial performance with a 20% revenue increase and improved margins. The company has raised its revenue and EBITDA margin guidance, indicating confidence in future growth. Strategic initiatives like expanding product offerings and market reach, along with double-digit growth in the oncology segment, are positive signals. The absence of negative market conditions or strategic risks further supports a positive sentiment. Although shareholder return plans are not mentioned, the overall outlook is strong, suggesting a positive stock price movement in the near term.